Antibody molecules which bind to human IL-17
View Patent ↗The invention relates to antibody molecules having specificity for antigenic determinants of IL-17, therapeutic uses of the antibody molecules and methods for producing said antibody molecules.
1. A neutralising antibody molecule having specificity for human IL-17, the antibody molecule comprising a heavy chain variable domain and a light chain variable domain, wherein the variable domain of the heavy chain comprises the sequence given in SEQ ID NO:1 for CDR-H1, the sequence given in SEQ ID NO:2 for CDR-H2 and the sequence given in SEQ ID NO:3 for CDR-H3, and wherein the variable domain of the light chain comprises the sequence given in SEQ ID NO:4 for CDR-L1, the sequence given in SEQ ID NO:5 for CDR-L2 and the sequence given in SEQ ID NO:6 for CDR-L3.
2. The antibody molecule according to claim 1 having a heavy chain comprising the sequence given in SEQ ID NO:9.
3. The antibody molecule according to claim 1 having a light chain comprising the sequence given in SEQ ID NO:7.
4. The antibody molecule according to claim 1 having a heavy chain comprising SEQ ID NO:9 and a light chain comprising the sequence given in SEQ ID NO:7.
5. The antibody molecule according to claim 1 having a heavy chain comprising the sequence given in SEQ ID NO:15 and a light chain comprising the sequence given in SEQ ID NO:11.
6. The antibody molecule of claim 1 wherein the antibody molecule is humanised.
7. The antibody molecule of claim 1 wherein said antibody molecule comprises a whole antibody or an antibody fragment comprising the heavy chain variable domain and the light chain variable domain.
8. The antibody molecule of claim 7 wherein said antibody fragment is selected from a Fab, Fab′, F(ab′) 2 , Fv, or scFv.
9. The antibody molecule of claim 1 further comprising a conjugated effector molecule.
10. The antibody molecule of claim 9 wherein said effector molecule is a PEG.
11. A pharmaceutical composition comprising the antibody molecule according claim 1 , in combination with one or more of a pharmaceutically acceptable excipient, diluent or carrier.
12. The pharmaceutical composition according to claim 11 , additionally comprising other active ingredients.